AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1-58. (canceled)

59. (currently amended) The sustained release oral dosage form of claim [[75]] 76, which can produce an average steady-state plasma concentration of the antiviral drug greater than a therapeutically effective concentration of the antiviral drug over a period of about 4 hours to about 24 hours.

60. (canceled)

61. (currently amended) The sustained release oral dosage form of claim [[75]] 76, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 4 hours after administration with no more than 30% by weight of the liquid antiviral drug composition being released within the first 1 hour after oral administration.

62. (currently amended) The sustained release oral dosage form of claim [[75]] 76, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 12 hours after administration with no more than 30% by weight of the liquid antiviral drug composition being released within the first 4 hours after oral administration.

63. (currently amended) The sustained release oral dosage form of claim [[75]] 76, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 24 hours after administration with no more than 30% by weight of the liquid antiviral drug composition being released within the first 12 hours after oral administration.

64-68. (canceled)

69. (currently amended) The sustained release oral dosage form of claim [[64]] 76, wherein the semipermeable layer comprises a semipermeable polymer and the expandable layer comprises a hydrophilic polymer.

70. (currently amended) The sustained release oral dosage form of claim 69, wherein the expandable layer further comprises a lubricant and/or an osmotically effective compound.

71. (currently amended) The sustained release oral dosage form of claim 70, wherein the hydrophilic polymer is present in an amount of up to 95 wt%, the osmotically effective compound is present in an amount of 0 wt% to 60 wt%, and the lubricant is present in an amount of 0 wt% to 5 wt% of the total composition of the expandable layer.

72. (currently amended) The sustained release oral dosage form of claim [[64]] 76, wherein the capsule is a gelatin capsule.

73-75. (canceled)

76. (new) A sustained release oral dosage form consisting of:

a capsule containing a liquid antiviral drug composition;

an exit orifice extending from an external surface of the capsule to an environment of use;

an expandable layer located within the capsule and remote from the exit orifice or contacting the external surface of the capsule;

a semipermeable layer surrounding the external surface of the capsule; and

an optional barrier layer located between the capsule and the expandable layer or between the liquid antiviral drug composition and the expandable layer;

wherein the liquid antiviral drug composition consists of an antiviral drug solubilized in a liquid non-ionic surfactant, the antiviral drug is present in the composition in an amount of about 5 wt% to about 60 wt%, the liquid non-ionic surfactant is present in the composition in an amount of about 20 wt% to about 95 wt%, and the liquid antiviral drug composition is substantially free of in-situ aggregation effect of the antiviral drug.

77. (new) The sustained release oral dosage form of claim 76, wherein the antiviral drug is a protease inhibitor.

78. (new) The sustained release oral dosage form of claim 77, wherein the protease inhibitor is selected from the group consisting of saquinavir, adefovir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine, and zalcitabin.

79. (new) The sustained release oral dosage form of claim 76, wherein the liquid non-ionic surfactant is polyoxyethylene 20 sorbitan monooleate and the antiviral drug is nelfinavir.

80. (new) The sustained release oral dosage form of claim 76, wherein the liquid non-ionic surfactant is selected from the group consisting of polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene 40 sorbitan monopalmitate, polyoxyethylene 60 sorbitan monostearate, polyoxyethylene 80 sorbitan monooleate, and polyoxyethylene 20 sorbitan monooleate.

81. (new) The sustained release oral dosage form of claim 76, for use in treating a condition in a subject responsive to the antiviral drug, wherein said condition is acquired immune deficiency syndrome (AIDS) associated with human immunodeficiency virus (HIV) infection in the subject.